IntelGenx Technologies Corp. Forms 3, 4 and 5: Warrants
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 11 rows, 11 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-03-08: Reporting owner ATAI Life Sciences N.V. | ATAI Life Sciences AG; Form 4; Security Warrant (Right to Buy); Transaction J Other acquisition or disposition (describe transaction).
- 2023-11-28: Reporting owner ATAI Life Sciences N.V. | ATAI Life Sciences AG; Form 4; Security Warrant (Right to Buy); Transaction P Open market or private purchase of non-derivative or derivative security.
- 2023-08-31: Reporting owner ATAI Life Sciences AG | ATAI Life Sciences N.V.; Form 4; Security Warrant (Right to Buy); Transaction P Open market or private purchase of non-derivative or derivative security.
- 2021-05-24: Reporting owner ATAI Life Sciences AG | ATAI Life Sciences B.V.; Form 3; Security Warrant (Right to Buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-03-08 | ATAI Life Sciences N.V. | ATAI Life Sciences AG 10% Owner | 10% Owner | 4 | Warrant (Right to Buy) Derivative · Indirect · By ATAI Life Sciences AG | J Other acquisition or disposition (describe transaction) | +4,000,000 4,000,000 owned after | $0.17 exercise price | 2024-03-12 | |
| 2023-11-28 | ATAI Life Sciences N.V. | ATAI Life Sciences AG 10% Owner | 10% Owner | 4 | Warrant (Right to Buy) Derivative · Indirect · By ATAI Life Sciences AG | P Open market or private purchase of non-derivative or derivative security | +4,053,750 16,052,850 owned after | $0.26 exercise price | 2024-03-12 | |
| 2023-08-31 | ATAI Life Sciences AG | ATAI Life Sciences N.V. 10% Owner | 10% Owner | 4 | Warrant (Right to Buy) Derivative · Indirect · By ATAI Life Sciences AG | P Open market or private purchase of non-derivative or derivative security | $0.26 exercise price | 2023-09-05 | ||
| 2021-05-24 holding as of filing | ATAI Life Sciences AG | ATAI Life Sciences B.V. 10% Owner | 10% Owner | 3 | Warrant (Right to Buy) Derivative · Direct | Holding | $0.35 exercise price | 2021-05-24 | ||
| 2021-05-24 holding as of filing | ATAI Life Sciences AG | ATAI Life Sciences B.V. 10% Owner | 10% Owner | 3 | Warrant (Right to Buy) Derivative · Direct | Holding | no price filed | 2021-05-24 | ||
| 2021-05-24 holding as of filing | ATAI Life Sciences AG | ATAI Life Sciences B.V. 10% Owner | 10% Owner | 3 | Warrant (Right to Buy) Derivative · Direct | Holding | no price filed | 2021-05-24 | ||
| 2018-05-08 | Godin Andre Officer (EVP and CFO) | 4/A | Warrants Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +15,380 15,380 owned after | $0.80 exercise price | 2018-05-11 | |
| 2018-05-08 | Godin Andre Officer (EVP and CFO) | 4 | Warrants Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +15,380 15,380 owned after | $0.80 exercise price | 2018-05-10 | |
| 2013-10-16 holding as of filing | Roadmap Capital Inc. Other (Investment Advisor) | 3 | warrants Derivative · Indirect · Canadian Investment advisor | Holding | $0.74 exercise price | 2013-10-16 | ||
| 2011-06-25 | BluMont Capital Corp 10% Owner | 4 | Warrant (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +30,000 255,000 owned after | $0.74 exercise price | 2012-04-13 | |
| 2010-08-27 | BluMont Capital Corp 10% Owner | 4 | Warrant (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +225,000 225,000 owned after | $0.50 exercise price | 2012-04-13 |